Companies Dominating the Advanced Therapy Medicinal Products Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Takeda Pharmaceutical Company Limited
- Gilead Sciences, Inc.
- Bluebird Bio, Inc.
- BioMarin Pharmaceuticals Inc.
- Vericel Corporation
- Mallinckrodt Pharmaceuticals
- UniQure N.V.
- JCR Pharmaceuticals Co., Ltd.
- Spark Therapeutics, Inc.
- Kolon TissueGene,Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of advanced therapy medicinal products is assessed at USD 14.47 billion.
The global advanced therapy medicinal products market is projected to grow from USD 13.21 billion in 2024 to USD 69.31 billion by 2037, exhibiting a CAGR of over 13.6% during the forecast period, between 2025 and 2037.
North America industry is anticipated to hold largest revenue share of 44% by 2037, attributed to higher cases of cancer and neurological disorder followed by investment by private companies for the development of advanced therapy medicinal products.
The major players in the market include Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene, Inc.
